Women with polycystic ovary syndrome show different levels of Alzheimer’s-related proteins in their blood than women without the condition, according to new research drawing fresh attention to a possible brain health connection.
Quick Take
- A 2024 study found women with polycystic ovary syndrome had different levels of Alzheimer’s-linked proteins compared to women without the condition.
- A large UK Biobank analysis found a higher crude rate of dementia in women with the condition, now also called polyendocrine metabolic ovarian syndrome.
- After adjusting for other health factors, that dementia link lost statistical significance, and researchers call the relationship unproven.
- Scientists say shared problems like insulin resistance and obesity may explain much of the connection, not the condition alone.
What The New Protein Study Actually Found
Researchers at the Royal College of Surgeons in Ireland tested blood from 143 women with polycystic ovary syndrome and 97 women without it. They used a precise protein-scanning tool and found higher levels of amyloid-related proteins and lower levels of another protein called alpha-synuclein, both patterns seen in Alzheimer’s disease. The protein pattern closely resembled one already linked to type 2 diabetes.
The study’s authors did not claim they had found proof of future Alzheimer’s disease. They described the pattern as a notable overlap worth investigating further and called for larger studies that track women over time to see whether the protein differences actually predict illness later in life.
A Bigger Database Tells A More Complicated Story
A separate analysis using the UK Biobank, one of the largest health databases in the world, looked at dementia rates directly. Women with the condition developed dementia at a rate of 6.0 per 1,000 person-years, compared to 5.2 per 1,000 for women without it. That sounds like a real difference on its face.
Once researchers adjusted for other health conditions tied to dementia risk, like diabetes, obesity, and heart disease, the gap stopped being statistically meaningful. The adjusted risk ratio came out close to even, with a wide range that included no difference at all. In plain terms, the raw numbers looked worrying, but the statistical backbone wasn’t there once other factors got accounted for.
Other studies add to the mixed picture. A retrospective look at more than 16,000 Canadian women with the condition found higher dementia rates and earlier onset than in matched women without it. But another UK Biobank review of a smaller group found no significant link at all. Different databases, different results, same open question.
Why Scientists Think There Might Be A Real Connection
The condition is already tied to insulin resistance, obesity, inflammation, and hormone imbalances, including an altered ratio between two reproductive hormones. Every one of those factors independently raises dementia risk on its own. A narrative review in the Journal of the Endocrine Society lays out this overlap and argues it deserves serious scientific attention rather than dismissal.
That overlap cuts both ways. It means a real biological link could exist. It also means the dementia signal researchers are seeing might come from the diabetes, weight, and inflammation that often travel alongside the condition, not from the condition itself. Separating those threads requires exactly the kind of long-term, carefully controlled study that hasn’t been done yet.
What Researchers Say Should Happen Next
Medical commentary accompanying this research has been consistent and careful. One write-up quotes investigators describing only a “potential relationship” and stating plainly that the current evidence “does not prove” the condition raises Alzheimer’s or dementia risk. That caution matters, especially given how easily a nuanced finding turns into an alarming headline once it spreads online.
PCOS/PMOS may be linked to increased Alzheimer’s disease and dementia risk https://t.co/8Meffvjikv
— Steven D Wexner MD, PhD (@SWexner) October 14, 2026
The condition affects roughly one in ten women of reproductive age, making this a question with enormous real-world stakes. Researchers now want long-term studies that follow diagnosed women for decades, track their brain scans and blood markers over time, and tease apart how much of any dementia risk comes from the condition itself versus the metabolic problems it tends to bring along. Until that work gets done, the honest answer is: possible connection, not yet proven cause.
Sources:
endocrine.org, d-nb.info, academic.oup.com, healthline.com, neurologyadvisor.com
